369 related articles for article (PubMed ID: 23479568)
21. [Analysis of clinical characteristics and outcome of patients with very high risk primary immunoglobulin light-chain amyloidosis].
Feng J; Huang XF; Zhang CL; Shen KN; Zhang CL; Sun J; Tian Z; Cao XX; Zhang L; Zhou DB; Li J
Zhonghua Xue Ye Xue Za Zhi; 2017 Feb; 38(2):107-111. PubMed ID: 28279033
[No Abstract] [Full Text] [Related]
22. Outcomes of Patients with Light Chain Amyloidosis Who Had Autologous Stem Cell Transplantation with 3 or More Organs Involved.
Al Saleh AS; Sidiqi MH; Muchtar E; Dispenzieri A; Buadi FK; Dingli D; Lacy MQ; Warsame RM; Gonsalves WI; Kourelis TV; Hogan WJ; Hayman SR; Kapoor P; Kumar SK; Gertz MA
Biol Blood Marrow Transplant; 2019 Aug; 25(8):1520-1525. PubMed ID: 31054986
[TBL] [Abstract][Full Text] [Related]
23. Validation of the Boston University staging system in AL amyloidosis.
Tomlinson R; Matigian N; Mollee P
Amyloid; 2019 Sep; 26(3):125-127. PubMed ID: 31145007
[No Abstract] [Full Text] [Related]
24. Utility of B-Type Natriuretic Peptide for Detecting Cardiac Involvement in Immunoglobulin Amyloidosis.
Kimishima Y; Yoshihisa A; Kiko T; Yokokawa T; Miyata-Tatsumi M; Misaka T; Oikawa M; Kobayashi A; Takeishi Y
Int Heart J; 2019 Sep; 60(5):1106-1112. PubMed ID: 31484874
[TBL] [Abstract][Full Text] [Related]
25. Outcomes among newly diagnosed AL amyloidosis patients with a very high NT-proBNP: implications for trial design.
Vaxman I; Kumar SK; Buadi F; Lacy MQ; Dingli D; Hwa Y; Fonder A; Hobbs M; Hayman S; Kourelis T; Warsame R; Muchtar E; Leung N; Kapoor P; Grogan M; Go R; Lin Y; Gonsalves W; Siddiqui M; Kyle RA; Rajkumar SV; Gertz MA; Dispenzieri A
Leukemia; 2021 Dec; 35(12):3604-3607. PubMed ID: 34021252
[No Abstract] [Full Text] [Related]
26. Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide, Troponin-T, and Growth-Differentiation Factor 15 in Adult Congenital Heart Disease.
Baggen VJ; van den Bosch AE; Eindhoven JA; Schut AW; Cuypers JA; Witsenburg M; de Waart M; van Schaik RH; Zijlstra F; Boersma E; Roos-Hesselink JW
Circulation; 2017 Jan; 135(3):264-279. PubMed ID: 27832613
[TBL] [Abstract][Full Text] [Related]
27. Prognostic values of novel biomarkers in patients with AL amyloidosis.
Kim D; Lee GY; Choi JO; Kim K; Kim SJ; Ju ES; Jeon ES
Sci Rep; 2019 Aug; 9(1):12200. PubMed ID: 31434944
[TBL] [Abstract][Full Text] [Related]
28. Decrease of B-type natriuretic peptide to less than 200 pg/mL predicts longer survival in cardiac immunoglobulin light chain amyloidosis.
Ishiguro K; Hayashi T; Igarashi T; Maruyama Y; Ikeda H; Ishida T; Shinomura Y
Int J Hematol; 2015 Aug; 102(2):200-4. PubMed ID: 26016720
[TBL] [Abstract][Full Text] [Related]
29. Combined use of bortezomib, cyclophosphamide, and dexamethasone induces favorable hematological and organ responses in Japanese patients with amyloid light-chain amyloidosis: a single-institution retrospective study.
Kikukawa Y; Yuki H; Hirata S; Ide K; Nakata H; Miyakawa T; Matsuno N; Nosaka K; Yonemura Y; Kawaguchi T; Hata H; Mitsuya H; Okuno Y
Int J Hematol; 2015 Feb; 101(2):133-9. PubMed ID: 25430082
[TBL] [Abstract][Full Text] [Related]
30. Cardiac biomarkers are prognostic in systemic light chain amyloidosis with no cardiac involvement by standard criteria.
Sharpley FA; Fontana M; Martinez-Naharro A; Manwani R; Mahmood S; Sachchithanantham S; Lachmann HJ; Gillmore JD; Whelan CJ; Hawkins PN; Wechalekar AD
Haematologica; 2020 May; 105(5):1405-1413. PubMed ID: 31399529
[TBL] [Abstract][Full Text] [Related]
31. A phase II trial of lenalidomide, dexamethasone and cyclophosphamide for newly diagnosed patients with systemic immunoglobulin light chain amyloidosis.
Cibeira MT; Oriol A; Lahuerta JJ; Mateos MV; de la Rubia J; Hernández MT; Granell M; Fernández de Larrea C; San Miguel JF; Bladé J;
Br J Haematol; 2015 Sep; 170(6):804-13. PubMed ID: 25974382
[TBL] [Abstract][Full Text] [Related]
32. Outcomes for patients with systemic light chain amyloidosis and Mayo stage 3B disease.
Theodorakakou F; Briasoulis A; Fotiou D; Petropoulos I; Georgiopoulos G; Lama N; Kelekis N; Repasos E; Migkou M; Stamatelopoulos K; Dimopoulos MA; Kastritis E
Hematol Oncol; 2023 Oct; 41(4):725-732. PubMed ID: 36974438
[TBL] [Abstract][Full Text] [Related]
33. Rationale, application and clinical qualification for NT-proBNP as a surrogate end point in pivotal clinical trials in patients with AL amyloidosis.
Merlini G; Lousada I; Ando Y; Dispenzieri A; Gertz MA; Grogan M; Maurer MS; Sanchorawala V; Wechalekar A; Palladini G; Comenzo RL
Leukemia; 2016 Oct; 30(10):1979-1986. PubMed ID: 27416985
[TBL] [Abstract][Full Text] [Related]
34. Comparison of different techniques to identify cardiac involvement in immunoglobulin light chain (AL) amyloidosis.
Aljama MA; Sidiqi MH; Dispenzieri A; Gertz MA; Lacy MQ; Buadi FK; Dingli D; Muchtar E; Fonder AL; Hayman SR; Hobbs MA; Gonsalves WI; Warsame RM; Kourelis T; Hwa YL; Kapoor P; Leung N; Go RS; Kyle RA; Rajkumar SV; Kumar SK
Blood Adv; 2019 Apr; 3(8):1226-1229. PubMed ID: 30975646
[TBL] [Abstract][Full Text] [Related]
35. Prognosis of Light Chain Amyloidosis With Preserved LVEF: Added Value of 2D Speckle-Tracking Echocardiography to the Current Prognostic Staging System.
Barros-Gomes S; Williams B; Nhola LF; Grogan M; Maalouf JF; Dispenzieri A; Pellikka PA; Villarraga HR
JACC Cardiovasc Imaging; 2017 Apr; 10(4):398-407. PubMed ID: 27639764
[TBL] [Abstract][Full Text] [Related]
36. Cardiorenal AL amyloidosis: risk stratification and outcomes based upon cardiac and renal biomarkers.
Rezk T; Lachmann HJ; Fontana M; Naharro AM; Sachchithanantham S; Mahmood S; Petrie A; Whelan CJ; Pinney JH; Foard D; Lane T; Youngstein T; Wechalekar AD; Hawkins PN; Gillmore JD
Br J Haematol; 2019 Aug; 186(3):460-470. PubMed ID: 31124579
[TBL] [Abstract][Full Text] [Related]
37. Multimarker Strategy for Heart Failure Prognostication. Value of Neurohormonal Biomarkers: Neprilysin vs NT-proBNP.
Bayes-Genis A; Barallat J; Galán A; de Antonio M; Domingo M; Zamora E; Gastelurrutia P; Vila J; Peñafiel J; Gálvez-Montón C; Lupón J
Rev Esp Cardiol (Engl Ed); 2015 Dec; 68(12):1075-84. PubMed ID: 26297179
[TBL] [Abstract][Full Text] [Related]
38. Clinical and prognostic significance of serum levels of von Willebrand factor and ADAMTS-13 antigens in AL amyloidosis.
Kastritis E; Papassotiriou I; Terpos E; Roussou M; Gavriatopoulou M; Komitopoulou A; Skevaki C; Eleutherakis-Papaiakovou E; Pamboucas C; Psimenou E; Manios E; Giannouli S; Politou M; Gakiopoulou H; Papadopoulou E; Stamatelopoulos K; Tasidou A; Dimopoulos MA
Blood; 2016 Jul; 128(3):405-9. PubMed ID: 27166361
[TBL] [Abstract][Full Text] [Related]
39. Dealing With High-Risk AL Amyloidosis Patients: A Single Hematologic Center Experience.
Riva M; Berno T; Cipriani A; Altinier S; Fedrigo M; Noventa F; Adami F
Clin Lymphoma Myeloma Leuk; 2021 Dec; 21(12):e970-e974. PubMed ID: 34489209
[TBL] [Abstract][Full Text] [Related]
40. Combined use of high-sensitivity cardiac troponin T and N-terminal pro-B type natriuretic peptide improves measurements of performance over established mortality risk factors in chronic heart failure.
de Antonio M; Lupon J; Galan A; Vila J; Urrutia A; Bayes-Genis A
Am Heart J; 2012 May; 163(5):821-8. PubMed ID: 22607860
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
